Maxwell Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maxwell Lee has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Howard Yang
Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
35 shared publications - Aleksandra M. Michalowski
Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville MD 20850, USA
29 shared publications - Andy D. Tran
Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
29 shared publications - Gamze Ayaz
National Cancer Institute 1 Cancer and Stem Cell Epigenetics, Laboratory of Cancer Biology and Genetics, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
29 shared publications - Hualong Yan
National Cancer Institute 1 Cancer and Stem Cell Epigenetics, Laboratory of Cancer Biology and Genetics, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
29 shared publications - Jing Huang
National Cancer Institute 1 Cancer and Stem Cell Epigenetics, Laboratory of Cancer Biology and Genetics, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
29 shared publications
Latest Publications
- 12 August 2026
- Published by Wiley in Head & Neck
Impact of Beers Criteria Medications in Elderly Patients With Head and Neck Cancer
Background: Head and neck cancer patients often experience polypharmacy due to complex treatments and comorbidities. The Beers Criteria is a list of potentially inappropriate medications (PIMs) for patients above age 65 developed by the American Geriatrics Society. We hypothesize that increased use of PIMs will be associated with inferior health and quality of life outcomes in elderly patients with head and neck cancer. Methods: We retrospectively examined patients aged ≥ 65 years with head and neck cancer diagnosed between 2011 and 2015 using SEER‐Medicare data, analyzing associations between Beers Criteria Medications (BCMs) and survival as a primary outcome. Emergency department (ED) utilization served as a secondary outcome. Results: Among 5213 patients (mean age 72.6 years), 44% received no BCMs within 1 year of diagnosis, while 41.3% received 1 BCM, 9.3% received 2 BCMs, and 5.4% received ≥ 3 BCMs. The most common medications prescribed were Lorazepam (12.3%), Zolpidem (7.9%), and Alprazolam (7.5%). Two‐year survival decreased with BCM use in a dose‐dependent fashion: 88.2% (0 BCM), 86.8% (1 BCM), 86.7% (2 BCMs), and 81.4% (≥ 3 BCMs; p < 0.001). BCM users had higher ED utilization in the year after diagnosis (mean 1.21 vs. 0.95 claims, p = 0.004). Conclusions: BCMs in elderly head and neck cancer patients were associated with inferior survival and increased healthcare utilization. These findings highlight the need for medication reconciliation and systematic reviews by multidisciplinary care teams to optimize outcomes in this vulnerable population.
- 12 August 2026
- Published by Wiley in Head & Neck
Impact of Beers Criteria Medications in Elderly Patients With Head and Neck Cancer
Background: Head and neck cancer patients often experience polypharmacy due to complex treatments and comorbidities. The Beers Criteria is a list of potentially inappropriate medications (PIMs) for patients above age 65 developed by the American Geriatrics Society. We hypothesize that increased use of PIMs will be associated with inferior health and quality of life outcomes in elderly patients with head and neck cancer. Methods: We retrospectively examined patients aged ≥ 65 years with head and neck cancer diagnosed between 2011 and 2015 using SEER‐Medicare data, analyzing associations between Beers Criteria Medications (BCMs) and survival as a primary outcome. Emergency department (ED) utilization served as a secondary outcome. Results: Among 5213 patients (mean age 72.6 years), 44% received no BCMs within 1 year of diagnosis, while 41.3% received 1 BCM, 9.3% received 2 BCMs, and 5.4% received ≥ 3 BCMs. The most common medications prescribed were Lorazepam (12.3%), Zolpidem (7.9%), and Alprazolam (7.5%). Two‐year survival decreased with BCM use in a dose‐dependent fashion: 88.2% (0 BCM), 86.8% (1 BCM), 86.7% (2 BCMs), and 81.4% (≥ 3 BCMs; p < 0.001). BCM users had higher ED utilization in the year after diagnosis (mean 1.21 vs. 0.95 claims, p = 0.004). Conclusions: BCMs in elderly head and neck cancer patients were associated with inferior survival and increased healthcare utilization. These findings highlight the need for medication reconciliation and systematic reviews by multidisciplinary care teams to optimize outcomes in this vulnerable population.
- Open Access
- 30 January 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (1) , e014067
Single-cell spatial transcriptomics uncovers niches that govern response to PD-1/PD-L1 blockade in cutaneous squamous cell carcinoma
Background: Neoadjuvant PD-1/PD-L1 blockade yields robust efficacy in advanced cutaneous squamous cell carcinoma (cSCC), yet many patients fail to achieve a complete or major pathologic response. The reasons why some patients experience response but others do not are unclear. Methods: We profiled cSCC specimens before, after 1 dose, and after 3–4 doses of PD-1/PD-L1 blockade to uncover resistance mechanisms and predict therapeutic response. In total, 27 patients across three cohorts, including two phase II trials, were studied. We created 1.7 mm tissue-core microarrays and performed single-cell spatial transcriptomics, including spatial clustering, gene-set enrichment, and spatial correlation analyses. Results: After profiling all samples, six distinct spatial niches emerged, each differentially enriched in responders versus non-responders. A high antigen presentation niche, B/plasma cell enriched niche, and inflammatory keratinocyte niche were more frequent in responders, whereas proliferative keratinocyte, low antigen presentation myeloid, and fibroblast-rich epithelial–mesenchymal transition niches prevailed in non-responders. Notably, spatial niche profiling on pretreatment samples outperformed PD-L1 status in predicting pathologic response. Each niche displayed unique gene coexpression modules, suggesting niche-specific resistance mechanisms. Individual tumor analyses revealed varied immune evasion strategies, including defective interferon-induced antigen presentation, immunosuppressive myeloid environments, and epithelial–mesenchymal transition. Conclusions: Our single-cell spatial transcriptomic approach identifies six spatial niches that predict immunotherapy response better than PD-L1 status using only 1.7 mm tissue cores and may inform the development of biomarkers. Our results further underscore the heterogeneity of resistance mechanisms among cSCC patients, highlighting the need for tailored therapeutic strategies.
- 30 January 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (1) , e014067
Open AccessSingle-cell spatial transcriptomics uncovers niches that govern response to PD-1/PD-L1 blockade in cutaneous squamous cell carcinoma
Background: Neoadjuvant PD-1/PD-L1 blockade yields robust efficacy in advanced cutaneous squamous cell carcinoma (cSCC), yet many patients fail to achieve a complete or major pathologic response. The reasons why some patients experience response but others do not are unclear. Methods: We profiled cSCC specimens before, after 1 dose, and after 3–4 doses of PD-1/PD-L1 blockade to uncover resistance mechanisms and predict therapeutic response. In total, 27 patients across three cohorts, including two phase II trials, were studied. We created 1.7 mm tissue-core microarrays and performed single-cell spatial transcriptomics, including spatial clustering, gene-set enrichment, and spatial correlation analyses. Results: After profiling all samples, six distinct spatial niches emerged, each differentially enriched in responders versus non-responders. A high antigen presentation niche, B/plasma cell enriched niche, and inflammatory keratinocyte niche were more frequent in responders, whereas proliferative keratinocyte, low antigen presentation myeloid, and fibroblast-rich epithelial–mesenchymal transition niches prevailed in non-responders. Notably, spatial niche profiling on pretreatment samples outperformed PD-L1 status in predicting pathologic response. Each niche displayed unique gene coexpression modules, suggesting niche-specific resistance mechanisms. Individual tumor analyses revealed varied immune evasion strategies, including defective interferon-induced antigen presentation, immunosuppressive myeloid environments, and epithelial–mesenchymal transition. Conclusions: Our single-cell spatial transcriptomic approach identifies six spatial niches that predict immunotherapy response better than PD-L1 status using only 1.7 mm tissue cores and may inform the development of biomarkers. Our results further underscore the heterogeneity of resistance mechanisms among cSCC patients, highlighting the need for tailored therapeutic strategies.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1-9 from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This file contains supplementary figure 1-9.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-9 from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This file contains supplementary figure 1-9.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This is supplementary Table 3.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This is supplementary Table 3.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This is supplementary Table 2.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This is supplementary Table 2.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This is supplementary Table 1.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This is supplementary Table 1.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4. from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This is supplementary Table 4.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4. from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
This is supplementary Table 4.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
Understanding functional interactions between cancer mutations is an attractive strategy for discovering unappreciated cancer pathways and developing new combination therapies to improve personalized treatment. However, distinguishing driver gene pairs from passenger pairs remains challenging. Here, we designed an integrated omics approach to identify driver gene pairs by leveraging genetic interaction analyses of top mutated breast cancer genes and the proteomics interactome data of their encoded proteins. This approach identified that PIK3CA oncogenic gain‐of-function (GOF) and CBFB loss‐of‐function (LOF) mutations cooperate to promote breast tumor progression in both mice and humans. The transcription factor CBFB localized to mitochondria and moonlighted in translating the mitochondrial genome. Mechanistically, CBFB enhanced the binding of mitochondrial mRNAs to TUFM, a mitochondrial translation elongation factor. Independent of mutant PI3K, mitochondrial translation defects caused by CBFB LOF led to multiple metabolic reprogramming events, including defective oxidative phosphorylation, the Warburg effect, and autophagy/mitophagy addiction. Furthermore, autophagy and PI3K inhibitors synergistically killed breast cancer cells and impaired the growth of breast tumors, including patient‐derived xenografts carrying CBFB LOF and PIK3CA GOF mutations. Thus, our study offers mechanistic insights into the functional interaction between mutant PI3K and mitochondrial translation dysregulation in breast cancer progression and provides a strong preclinical rationale for combining autophagy and PI3K inhibitors in precision medicine for breast cancer.Significance:CBFB-regulated mitochondrial translation is a regulatory step in breast cancer metabolism and synergizes with mutant PI3K in breast cancer progression.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Dysregulation of Mitochondrial Translation Caused by CBFB Deficiency Cooperates with Mutant PIK3CA and Is a Vulnerability in Breast Cancer
Understanding functional interactions between cancer mutations is an attractive strategy for discovering unappreciated cancer pathways and developing new combination therapies to improve personalized treatment. However, distinguishing driver gene pairs from passenger pairs remains challenging. Here, we designed an integrated omics approach to identify driver gene pairs by leveraging genetic interaction analyses of top mutated breast cancer genes and the proteomics interactome data of their encoded proteins. This approach identified that PIK3CA oncogenic gain‐of-function (GOF) and CBFB loss‐of‐function (LOF) mutations cooperate to promote breast tumor progression in both mice and humans. The transcription factor CBFB localized to mitochondria and moonlighted in translating the mitochondrial genome. Mechanistically, CBFB enhanced the binding of mitochondrial mRNAs to TUFM, a mitochondrial translation elongation factor. Independent of mutant PI3K, mitochondrial translation defects caused by CBFB LOF led to multiple metabolic reprogramming events, including defective oxidative phosphorylation, the Warburg effect, and autophagy/mitophagy addiction. Furthermore, autophagy and PI3K inhibitors synergistically killed breast cancer cells and impaired the growth of breast tumors, including patient‐derived xenografts carrying CBFB LOF and PIK3CA GOF mutations. Thus, our study offers mechanistic insights into the functional interaction between mutant PI3K and mitochondrial translation dysregulation in breast cancer progression and provides a strong preclinical rationale for combining autophagy and PI3K inhibitors in precision medicine for breast cancer.Significance:CBFB-regulated mitochondrial translation is a regulatory step in breast cancer metabolism and synergizes with mutant PI3K in breast cancer progression.
- 15 July 2025
- Published by Elsevier in Oral Oncology
- Vol. 168, 107467
Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department
- 15 July 2025
- Published by Elsevier in Oral Oncology
- Vol. 168, 107467
Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S1-9 from Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer
This file contains supplementary figure 1-9.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1-9 from Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer
This file contains supplementary figure 1-9.